Company: GANX
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001104659-25-068103
Chunk: 27

Company: Gain Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 27
---
 under our equity incentive plans or we otherwise issue additional shares of common stock in the future at a price less than the public offering price, there will be further dilution to new investors.

S-18

TABLE OF CONTENTS

UNDERWRITING Newbridge Securities Corporation (“Newbridge” or the “underwriter”) is acting as sole underwriter of this offering. We entered into an underwriting agreement with Newbridge with respect to the securities subject to this offering. Subject to the terms and conditions stated in the underwriting agreement dated the date of this prospectus supplement, the underwriter has agreed to purchase, and we have agreed to sell to the underwriter, the number of shares of common stock, Pre-Funded Warrants and Common Warrants shown in the table below.

| UNDERWRITER                      | ​ | ​ | NUMBER OFSHARES | ​ | ​ | NUMBER OFPRE-FUNDEDWARRANTS | ​ | ​ | NUMBER OFCOMMONWARRANTS | ​ |
| Newbridge Securities Corporation | ​ | ​ | ​               | ​ | ​ | ​                           | ​ | ​ | ​                       | ​ |

The underwriting agreement provides that the obligations of the underwriter to purchase the shares of common stock and Pre-Funded Warrants and the accompanying Common Warrants included in this offering are subject to approval of legal matters by counsel and to other conditions. The underwriting agreement provides that the underwriter will purchase all of the shares of common stock and Pre-Funded Warrants and accompanying Common Warrants if any of them are purchased. Shares of our common stock and Pre-Funded Warrants and the accompanying Common Warrants sold by the underwriter to the public will initially be offered at the public offering prices set forth on the cover of this prospectus supplement. In addition, the underwriter may offer some of the securities to other securities dealers at such price less a concession of $ per set of securities. After the initial offering of the securities, the public offering price or any other term of the offering may be changed by the underwriter. Underwriting discounts and commissions We are offering shares of common stock, Pre-Funded Warrants to purchase up to shares of common stock, and Common Warrants to purchase up to shares of common stock pursuant to this prospectus supplement. The following table shows the effective public offering price per share of common stock and accompanying Common Warrant, the effective public offering price per Pre-Funded Warrant and accompany Common Warrant, and total public offering price, underwriting discounts and commissions, and proceeds before